The minimal clinically important difference of the Severe Respiratory Insufficiency questionnaire in severe COPD. Issue 6 (17th December 2020)

• Record Type: Journal Article
• Authors: Raveling, Tim; Kort, Janine; Bladder, Gerrie; Windisch, Wolfram; Wijkstra, Peter J.; Duiverman, Marieke L.
• Is Part Of: European respiratory journal. Volume 56:Issue 6(2020)
• Publication Date: 2020-12-17
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01334-2020
• Languages: English
• ISSNs: 0903-1936

Abstract

The Severe Respiratory Insufficiency Questionnaire (SRI) was developed to measure health-related quality of life (HRQoL) specifically in patients with chronic hypercapnic respiratory failure (CHRF) [1]. It has been validated for patients with a broad spectrum of underlying diseases, including patients with COPD [2], and has been used extensively in trials investigating noninvasive ventilation (NIV) for CHRF due to different aetiologies. Furthermore, its use in clinical practice for care quality monitoring is increasing, and might increase further since convenient applications for mobile devices recently became available. Unfortunately, the minimal clinically important difference (MCID) has not been determined. Therefore, it remains difficult to interpret the improvements in HRQoL or to use the SRI as a primary outcome in clinical trials as the MCID determinates the sample size needed. Therefore, we aimed to estimate the MCID of the SRI in a group of severe COPD patients treated with NIV. The SRI is frequently used to measure quality of life in severe COPD patients treated with NIV, but its MCID is unknown. This paper shows MCID estimates between 4.5–6.2, so that we suggest an increase of approximately 5 points is clinically relevant. https://bit.ly/3e0M7MT